Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
The global nursing workforce has grown by nearly two million over the past five years, yet major disparities in distribution continue to impede progress towards universal health coverage (UHC) and global health goals, according to the State of the World’s Nursing 2025 report released on 12 May by the World Health Organization (WHO), International Council of Nurses (ICN), and partners.
As of 2023, there are 29.8 million nurses worldwide, up from 27.9 million in 2018. The report also notes a decline in the global nursing shortage, from 6.2 million in 2020 to 5.8 million in 2023. However, the report cautions that the improvements are not evenly shared across regions and income levels, leaving many low- and middle-income countries struggling with persistent shortfalls.
A striking imbalance in nurse distribution persists: 78 per cent of the world’s nurses are based in countries that account for just 49 per cent of the global population. High-income nations host nearly half the global nursing workforce, despite representing only 17 per cent of the world’s population. This concentration has raised concerns that many countries are being left behind, particularly in Africa and the Eastern Mediterranean, where shortages are expected to remain critical.
The WHO forecasts a continued reduction in the global nursing shortage, projecting a shortfall of 4.1 million by 2030. However, almost 70 per cent of this gap is expected to be concentrated in the African and Eastern Mediterranean regions, which could seriously undermine healthcare delivery and preparedness for future health emergencies.
Low-income countries are seeing faster growth in nurse graduate numbers, yet many face challenges in translating this into increased nurse availability. Factors such as rapid population growth, limited job creation, and restricted resources mean these countries are unable to retain and integrate newly qualified nurses into the workforce. The report urges governments to prioritise domestic investment in health systems to ensure graduate absorption and improve employment conditions.
Meanwhile, high-income countries are experiencing a demographic shift in their nursing workforce. Around 19 per cent of nurses globally are expected to retire within the next decade. In some high-income nations, retirements are likely to exceed new entrants, raising the risk of workforce gaps and reduced mentoring capacity for younger nurses.
International migration continues to play a key role in shaping nursing workforces. Globally, one in seven nurses is foreign-born, with high-income countries depending on international recruitment for nearly a quarter of their workforce. By contrast, foreign-born nurses make up only 1–8 per cent of the workforce in lower-income countries. The report calls for stronger bilateral agreements to ensure ethical recruitment and mutual benefits for both source and destination countries.
Gender equity remains a central concern. Women comprise 85 per cent of the global nursing workforce, yet opportunities for advancement and leadership remain limited in many settings. While 82 per cent of countries report having a senior government nursing officer, only 25 per cent of low-income countries offer structured leadership development programmes for nurses.
The report also highlights progress in recognising advanced nursing roles, with 62 per cent of countries now reporting the existence of such positions, up from 53 per cent in 2020. Advanced practice nurses have been shown to enhance access to care, particularly in underserved areas.
Mental health and wellbeing support for nurses remains inadequate. Despite increased workloads and stress during the COVID-19 pandemic, only 42 per cent of countries surveyed have formal provisions for mental health support. The lack of such measures is seen as a barrier to retaining experienced staff and ensuring quality care.
The State of the World’s Nursing 2025 report sets out key policy recommendations for the 2026–2030 period. These include expanding and equitably distributing nursing jobs, aligning education systems with workforce needs, improving pay and working conditions, and strengthening regulation and leadership. Additional priorities focus on preparing nurses for digital healthcare delivery, addressing gender pay gaps, and supporting those working in conflict zones and climate-affected areas.
Pam Cipriano, President of the ICN, said the report served as an “important milestone” in tracking global efforts to strengthen nursing. “Delivering on UHC depends on recognising the true value of nurses and empowering them to lead health system improvements,” she said.
WHO Director-General Dr Tedros Adhanom Ghebreyesus welcomed the progress but warned that deep inequalities persist. “This report is a guide to where we are and what we must do next,” he said. “Countries must act quickly to close the gaps and support the nursing workforce.”
The report draws on data from 194 countries and is part of WHO’s efforts to monitor and strengthen the global health workforce as part of the push to meet the Sustainable Development Goals by 2030.
Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
Health officials are investigating possible genetic causes behind the side-effects
Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
Adverse drug reactions cost the NHS an estimated £2.2bn annually
Health watchdog investigates spike in serious side-effects from GLP-1 drugs
UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.
The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.
What is acute pancreatitis?
Acute pancreatitis is a sudden inflammation of the pancreas, the gland located behind the stomach that helps with digestion. Symptoms typically include severe abdominal pain, nausea, and fever, and the condition often requires hospital treatment. In rare cases, it can be fatal.
Though pancreatitis is listed as an “uncommon” side-effect of GLP-1 medications in patient information leaflets – meaning it may affect around one in 100 people – the MHRA has seen a notable rise in reported incidents, particularly in 2025.
Since the start of the year, there have been 22 reports involving semaglutide (Ozempic and Wegovy) and 101 involving tirzepatide (Mounjaro).
Study launched to explore potential genetic link
To understand the possible causes of these side effects, particularly in light of rising usage of these medications, the MHRA is inviting affected patients to take part in a research study through the Yellow Card Biobank. The initiative, run by Genomics England, will collect saliva samples and other data to explore any genetic factors that may be influencing patient response to GLP-1 drugs.
An MHRA spokesperson stated: “Alongside increased usage, we are seeing an upturn in the number of Yellow Card reports mentioning GLP-1 medicines and acute pancreatitis.”
While no known genetic link has yet been established, the MHRA said genetic variations could help explain why some patients experience adverse reactions to certain medications. The agency is urging both patients and health professionals to report suspected side-effects related to these drugs.
Adverse reactions place burden on NHS
Research shows that one in six hospital admissions is caused by an adverse drug reaction, and around a third of those could potentially be avoided through genetic testing. The financial cost is also significant – the NHS spends over £2.2 billion each year on hospital stays linked to adverse reactions alone.
Dr Alison Cave, chief safety officer at the MHRA, highlighted the need for more personalised approaches to medicine: “Evidence shows that almost a third of side-effects to medicines could be prevented with the introduction of genetic testing.”
Manufacturers respond to rising concerns
In response to the reports, drugmakers Lilly and Novo Nordisk reiterated their commitment to patient safety and advised that side effects should always be reported and discussed with healthcare professionals.
A spokesperson for Lilly, which manufactures Mounjaro, said: “Patient safety is Lilly’s top priority. We take reports seriously and actively monitor, evaluate and report safety information for all our medicines.”
The Mounjaro leaflet identifies acute pancreatitis as an uncommon side-effect, advising patients to consult their doctor before using the drug if they have a history of the condition.
Novo Nordisk UK, which produces Ozempic and Wegovy, issued a similar statement: “Patient safety is of the utmost importance to Novo Nordisk… The known risks and benefits of GLP-1 medicines are described in the product information. We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional.”
Both companies said they were continuously collecting safety data and working with authorities to ensure ongoing monitoring and understanding of their treatments.
What should patients do?
Health officials are encouraging patients who have experienced severe symptoms such as abdominal pain, nausea, or fever after taking these medications to report their experiences to the Yellow Card scheme. Hospitalised individuals may be contacted to participate in the Biobank study.
While the overall safety profile of GLP-1 medicines remains positive, the MHRA has stressed the importance of vigilance as demand for these weight loss and diabetes drugs continues to grow.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Health officials expect the rollout to benefit around 220,000 adults over the next 3 years
NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
The programme aims to support 220,000 people over three years
Eligible patients must have a BMI over 40 and at least four obesity-related health issues
GP leaders raise concerns over increased workload
Pharmacists urge a broader weight management approach
NHS expands obesity treatment with Mounjaro
The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.
Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.
GPs express concern over added burden
While the rollout has been welcomed as a major step in tackling severe obesity, some family doctors have expressed concern over the operational challenges it may bring. The British Medical Association and other GP leaders have highlighted the need for additional training, resources and time to manage the expected rise in patient demand.
They warn that without extra support, the move could add further pressure to already stretched primary care services.
Calls for a comprehensive approach
Pharmacy experts and health professionals have stressed that Mounjaro should not be viewed as a standalone solution. Instead, they argue that it must be integrated into a broader weight management strategy that includes dietary changes, physical activity, and behavioural support.
There are also concerns about potential pressure on drug supplies as demand increases. Experts suggest that clear guidance on prescription protocols and supply management will be crucial to avoid shortages.
A targeted step in tackling obesity
The introduction of Mounjaro is part of the NHS’s wider effort to address rising obesity levels in the UK, which are closely linked to long-term health complications and increased strain on the health system. By targeting the most at-risk individuals, health officials hope the new measure will reduce future hospitalisations and improve overall health outcomes.
Keep ReadingShow less
Around 85% of the projected deaths are likely to involve people over the age of 65
Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.
Climate change driving deadly temperatures
Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.
The scientists estimate that human activity has increased the temperatures experienced during this heatwave by 2°C to 4°C, pushing the mercury beyond safe levels for many, particularly the elderly and those with underlying health conditions.
Dr Garyfallos Konstantinoudis from Imperial College London, who helped conduct the analysis, said: “Heatwaves are silent killers – people who lose their lives in them typically have pre-existing health conditions and rarely have heat listed as a contributing cause of death. This real-time analysis reveals the hidden toll of heatwaves, and we want it to help raise the alarm.”
Deaths concentrated among older adults
The analysis, based on decades of UK temperature and mortality data across more than 34,000 locations in England and Wales, projects around 570 excess deaths between Thursday and Sunday. Of these, approximately 129 are expected in London. Scientists believe the figure may be underestimated, as early summer heatwaves often catch people unprepared.
Around 85% of the projected deaths are likely to involve people over the age of 65, who are particularly vulnerable to heat stress. Other at-risk groups include infants, pregnant individuals, and people with cardiovascular or respiratory conditions.
Dr Malcolm Mistry from the London School of Hygiene & Tropical Medicine (LSHTM), who contributed to the study, warned: “Exposure to temperatures in the high 20s or low 30s may not seem dangerous, but they can be fatal, particularly for people aged over 65, infants, pregnant people, and those with pre-existing health conditions.”
Health and emergency services under pressure
The UK Health Security Agency (UKHSA) issued an amber heat-health alert on Thursday, which is set to remain in effect until 9 am on Monday. The warning highlights a risk of increased deaths and severe impacts on health and social care systems.
Medical professionals have reported a rise in heat-related illnesses. Dr Lorna Powell, an urgent care doctor in East London, said: “We are seeing cases of heat exhaustion rising. It can quickly trigger more serious illnesses, as dehydration sets in and the cardiovascular system becomes overwhelmed.”
The UKHSA advises people to stay out of the sun between 11 am and 3 pm, drink plenty of fluids, keep indoor spaces cool, and check in on vulnerable neighbours and family members. Data from a recent study indicates that approximately 80% of UK homes overheat during summer, further exacerbating health risks for residents.
Urban areas face greater risk
City dwellers, especially those in poorly ventilated flats, face higher health risks during heatwaves. Heat becomes trapped in buildings, leading to prolonged exposure, especially at night when outdoor temperatures remain high.
Professor Antonio Gasparrini of LSHTM, another contributor to the analysis, said: “When temperatures push past the limits populations are acclimatised to, excess deaths can increase very rapidly. Every fraction of a degree of warming will cause more hospital admissions and heat deaths, putting more strain on the NHS.”
Poor preparedness criticised
Between 2020 and 2024, more than 10,000 people died in the UK due to heatwaves, according to UKHSA data. Yet in April 2025, the government’s climate advisers criticised the UK’s readiness to deal with extreme heat, calling preparations “inadequate, piecemeal and disjointed”.
Despite growing awareness of climate-related risks, systemic changes to improve resilience, such as retrofitting homes and bolstering healthcare capacity, have been limited.
Government removes barriers to home EV chargers
As part of broader environmental measures, the UK government recently eliminated the requirement for planning permission to install electric vehicle (EV) chargers at homes and businesses. This change is estimated to save an average of £1,100 per installation, according to the Department for Transport, and may aid the shift to low-carbon transport. While unrelated to heatwave policy, the move reflects the government’s push for green infrastructure.
Air quality worsens amid heat
Alongside the heat, a spike in air pollution has raised additional concerns. London has been issued a high ozone pollution alert, with people suffering from respiratory conditions such as asthma advised to avoid outdoor exercise.
Heatwaves becoming more frequent and intense
Global data shows that extreme heat causes more deaths than floods, hurricanes, or earthquakes. According to insurer Swiss Re, heatwaves are responsible for about 500,000 deaths globally each year. “Extreme heat events are more dangerous than natural catastrophes in terms of human lives lost, yet the true cost is only starting to come to light,” said Nina Arquint, chief executive of corporate solutions at Swiss Re.
In 2024, the planet recorded its hottest year on record, driven by climate change and rising emissions. Carbon dioxide levels from fossil fuels continue to increase, pushing the world closer to dangerous temperature thresholds.
A recent report by the UK Climate Change Committee estimates that if global temperatures rise by 2°C above pre-industrial levels, annual heat-related deaths in the UK could exceed 10,000 by 2050.
The scientists behind the current analysis hope that quantifying the hidden human cost of heatwaves will prompt more urgent action to reduce emissions and prepare the UK for a hotter future.
Keep ReadingShow less
'The Lancet' and presentations at the American Diabetes Association’s 2025
A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.
Record weight loss from Amycretin injections
Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.
Amycretin, developed by Novo Nordisk, the same pharmaceutical company behind Wegovy and the Type 2 diabetes treatment Ozempic, works by targeting both the GLP-1 and amylin receptors. These receptors help control blood sugar levels and suppress appetite.
Strong results for oral version
In addition to the injectable form, a parallel study explored amycretin in tablet form. Conducted over 12 weeks and involving 144 adults, the trial showed those on the highest daily dose (100mg) lost 13.1 per cent of their body weight – a substantial result for an oral medication over such a short period.
Both studies also reported improvements in metabolic and glycaemic health. The authors wrote that amycretin “effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity”. They called for longer and larger trials to assess long-term safety and optimise the dosing regimen.
Pills could overtake jabs in the future
While the injectable version delivered record weight loss, the promising results from the pill suggest oral treatments could soon rival or even surpass jabs in convenience and effectiveness.
Health experts have described the development of an effective pill as a potential “game-changer” in tackling obesity. Professor Jason Halford, former president of the European Association for the Study of Obesity, said: “They will be easier to produce, store and use, and this should mean they could become more widely available. That would produce a significant impact on the nation’s health.”
Limited NHS rollout as private demand surges
Obesity remains a major issue in the UK, with around two in three adults considered overweight or obese. The NHS is set to begin prescribing GLP-1 injections from late June 2025, although the initial rollout will be limited. Around 220,000 people are expected to be treated through the NHS within the next three years.
Eligibility criteria are strict, covering only the most obese patients with at least four chronic health conditions linked to excess weight. Meanwhile, private use of these medications has surged, with an estimated 1.5 million people in the UK having already purchased jabs like Wegovy.
Wegovy also shows promise at higher doses
Separately, another study presented at the ADA meeting focused on Wegovy (semaglutide), examining the effects of a higher weekly dose of 7.2mg. This led to average weight loss of 20.7 per cent over 72 weeks, up from 13.7 per cent at the standard dose used in earlier trials.
As competition intensifies in the weight-loss drug market, amycretin’s early results, particularly in tablet form, suggest it could play a major role in the future of obesity treatment.
Keep ReadingShow less
Hogan’s current hospital stay follows a neck fusion surgery he underwent in May 2025
WWE Hall of Famer Hulk Hogan has been hospitalised for ongoing neck and back issues, but representatives have confirmed he is not in critical condition, dismissing online speculation suggesting otherwise.
The 71-year-old wrestling icon, whose real name is Terry Bollea, was reported by TMZ Sports to be undergoing treatment related to injuries sustained during his decades-long in-ring career. His representative said Hogan is already mobile again and “not on his deathbed”, following false claims made on air by Florida radio personality Bubba the Love Sponge.
The speculation began after Bubba stated he had heard Hogan’s health had declined significantly and that family members were being called to say their goodbyes. However, he admitted the information was second-hand and unverified at the time of broadcast.
— (@)
In reality, Hogan’s current hospital stay follows a neck fusion surgery he underwent in May 2025, which was described as successful. He has undergone numerous operations over the years to treat wear and tear from wrestling, particularly to his spine, hips and knees.
Despite his physical challenges, Hogan has continued to make public appearances. His most recent confirmed outing was in January 2025 on WWE Raw, where he promoted his Real American Beer brand during the programme’s Netflix launch. The segment received a mixed reaction from the crowd.
Hogan remains one of the most recognisable figures in professional wrestling, having helped define the industry during the 1980s boom. He held multiple world titles and was central to WWE's rise to global popularity, later moving to WCW and becoming a founding member of the nWo.
His team has confirmed there is no cause for alarm, and that his current hospitalisation is part of ongoing care rather than any emergency. No further surgeries have been announced at this stage.